Patents Assigned to Borah, Inc.
  • Patent number: 12404286
    Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.
    Type: Grant
    Filed: November 16, 2023
    Date of Patent: September 2, 2025
    Assignee: BORAH, INC.
    Inventors: Alan Long, Chun Yu Liu, Chunliang Liu, Yasheen Zhou, Shon R. Pulley, Keith Andrew Newton Graham
  • Patent number: 12358932
    Abstract: The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: July 15, 2025
    Assignee: BORAH, INC.
    Inventors: Yasheen Zhou, Chun Yu Liu, Chunliang Liu, Yong-Kang Zhang
  • Patent number: 11827657
    Abstract: The present invention describes novel boron containing pyrazole compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described are methods of treating inflammation, auto-immune diseases, cancer, and other conditions that are susceptible to the inhibition of a Janus kinase by administering a compound herein described.
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: November 28, 2023
    Assignees: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., BORAH, INC.
    Inventors: Alan Long, Chun Yu Liu, Chunliang Liu, Yasheen Zhou, Shon R. Pulley, Keith Andrew Newton Graham
  • Patent number: 11306108
    Abstract: The present invention describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the invention have activity as Janus kinase (JAK) inhibitors and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK by administering a compound herein described.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: April 19, 2022
    Assignee: Borah, Inc.
    Inventors: Yasheen Zhou, Chunliang Liu, Yong-Kang Zhang, Marissa Aubrey, Chun Yu Liu